ELEVATION ONCOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.02 USD | -1.23% |
|
+8.94% | +648.60% |
| 02:07pm | Piper Sandler Starts Elevation Oncology With Overweight Rating, $10 Price Target | MT |
| 05-14 | Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target | MT |
Presenter SpeechPriyanka Grover (Analysts)Hi, everyone. Good morning. My name is Priyanka Grov...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.
Calendar
13/06/2024
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.07
USD
Average target price
7.8
USD
Spread / Average Target
+91.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +648.60% | 222M | |
| +11.91% | 114B | |
| +11.60% | 105B | |
| -4.68% | 23.83B | |
| -0.82% | 21.73B | |
| -10.12% | 18.1B | |
| -42.12% | 16.34B | |
| -17.47% | 16.13B | |
| +2.77% | 13.75B | |
| +34.58% | 11.76B |
- Stock Market
- Equities
- ELEV Stock
- News Elevation Oncology, Inc.
- Transcript : Elevation Oncology, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023 09
